Repligen (RGEN) P/E ratio

P/E ratio · fiscal 2025
190.5×

The P/E ratio of Repligen (RGEN) was 190.5× at the end of fiscal 2025 (December 31, 2025). Figures as of 18 Nov 2026, 07:09 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio, fiscal 2025
190.5×
Highest on record
243.0×fiscal 2023
Lowest on record
14.0×fiscal 2012
Fiscal years on record
132012–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Repligen P/E ratio, in more detail

Across the 13 fiscal year-ends on record (2012–2025), the highest was 243.0× in fiscal 2023 and the lowest 14.0× in fiscal 2012.

History · 13 fiscal years

P/E ratio at each fiscal year-end

Repligen P/E ratio, year by year

Repligen (RGEN) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
2025190.5×—$163.86$0.86
2024——$143.94-$0.46
2023243.0× 365.0% up$179.80$0.74
202252.3× 55.8% down$169.31$3.24
2021118.2× 31.5% down$264.84$2.24
2020172.6× 17.9% down$191.63$1.11
2019210.2× 47.5% up$92.50$0.44
2018142.5× 182.9% up$52.74$0.37
201750.4× 44.4% down$36.28$0.72
201690.6× 10.3% down$30.82$0.34
2015101.0× 27.6% up$28.29$0.28
201479.2× 190.3% up$19.80$0.25
201327.3× 95.5% up$13.64$0.50
201214.0×—$6.28$0.45
2011——$3.47—
2011——$3.74$0.00
2010——$4.06-$0.13

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

P/E ratio at health care companies of similar size

P/E ratio of Repligen and comparable companies
CompanyP/E ratio
DaVita DVA13.1×
Halozyme Therapeutics HALO24.0×
Universal Health Services UHS8.0×
Bio-Techne TECH66.6×

Price over the last twelve months' earnings per share, as the market data feed reports it.

More on RGEN

Repligen, figure by figure

Repligen (RGEN) overview: price, valuation and scorecardAll health care companies by market value

Repligen P/E ratio: questions and answers

What is Repligen's P/E ratio?

The P/E ratio of Repligen (RGEN) was 190.5× at the end of fiscal 2025 (December 31, 2025).

What are the highest and lowest P/E ratio figures on record for Repligen?

Across the 13 fiscal year-ends on record (2012–2025), the highest was 243.0× in fiscal 2023 and the lowest 14.0× in fiscal 2012.

How is Repligen's P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Repligen (RGEN) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RGEN/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.